Doxiverse Staff - August 2026
The Centers for Medicare & Medicaid Services has approved a New Technology Add-on Payment (NTAP) for Aidoc's CARE Multi-Triage CT Body device, an FDA-cleared AI tool that flags suspected urgent findings on CT scans of the chest, abdomen, and pelvis. The approval, part of CMS's finalized Fiscal Year 2027 Inpatient Prospective Payment System (IPPS) rule published August 4, gives hospitals a standardized Medicare billing pathway for the technology starting October 1, 2026.
Why it matters: This gives hospital finance and radiology leadership a concrete, dated reimbursement figure to build into purchasing decisions for CT triage AI and it's one of the clearer examples yet of Medicare creating a specific payment mechanism for a diagnostic AI tool built on a broader "foundation model" rather than a narrow, single-task algorithm.
What Happened
NTAP is a Medicare mechanism that provides hospitals an extra payment, on top of the standard diagnosis-related group payment, to help offset the cost of adopting new, high-cost inpatient technologies. According to CMS's finalized rule and reporting from Radiology Business (citing the American College of Radiology's summary of the rule), Medicare will pay up to $137.53 per eligible case in 2027 for use of Aidoc's device - a figure the ACR says represents roughly 65% of the technology's average cost. Eligible cases will be identified by a specific procedure code, XEZ5XKC, covering computer-aided triage and notification for CT imaging of the chest, abdomen, and pelvis.
Aidoc's CARE Multi-Triage CT Body received FDA Breakthrough Device Designation in September 2025 and FDA clearance in January 2026, both predating this reimbursement decision. The device is built on Aidoc's CARE diagnostic AI foundation model and is cleared to help clinicians triage CT studies by flagging a broad set of urgent findings, such as suspected appendicitis or bowel obstruction, so radiologists can prioritize time-sensitive cases. Reimbursement eligibility runs for three years from the October 1 start date.
This single approval sits within a larger CMS action: according to Radiology Business's reporting on the same finalized rule, CMS approved a total of 22 new products for FY2027 NTAP payments through what the agency calls the "alternative" pathway (available to FDA breakthrough-designated technologies), along with 8 more through the traditional pathway, for a combined additional $779 million in NTAP spending across all approved technologies, not just AI tools in fiscal 2027.
Aidoc CEO Elad Walach said in the company's release that the NTAP program can play an important role in helping hospitals invest in inpatient clinical technologies.
What This Means for Hospitals and Radiology Departments
For hospitals already using or evaluating Aidoc's CT triage tool, this converts what may have previously been an unclear or absent reimbursement picture into a specific, dated payment amount tied to a specific billing code, useful for building a concrete cost-benefit case starting in the FY2027 budget cycle. Aidoc's own release notes that hospitals should still evaluate their individual cases against CMS's requirements to confirm eligibility, since NTAP reimbursement applies only to qualifying Medicare Fee-for-Service inpatient cases, not all uses of the device.
What's Still Unsettled
The most significant caveat here isn't about this specific device, it's about the pathway it came through. According to Radiology Business's reporting on the final rule, CMS is repealing the "alternative" NTAP pathway (the one that only required FDA breakthrough-device status, without proof of substantial clinical improvement) for new applications starting in fiscal year 2028. Going forward, CMS says it will require all NTAP applicants to meet the more stringent "traditional" pathway standard, which does require demonstrated substantial clinical improvement. That means this Aidoc approval reflects a regulatory standard that will not be available to the next wave of AI devices seeking similar reimbursement that is worth keeping in mind when evaluating whether other AI vendors' reimbursement timelines will look similar to this one.
It's also worth noting the underlying figures in this article come from two different levels of sourcing: the NTAP approval itself, the effective date, and the CEO quote are confirmed directly from Aidoc's own press release; the specific $137.53 payment cap, the total count of approved technologies, and the $779 million aggregate spending figure come from Radiology Business's independent reporting on the CMS final rule and the American College of Radiology's summary of it, not from Aidoc's release directly. Readers wanting the underlying regulatory language itself should consult the final rule directly in the Federal Register.
Sources:
- Aidoc press release, PRNewswire, August 13, 2026. https://www.prnewswire.com/news-releases/aidocs-care-body-ct-multi-triage-receives-eligibility-for-medicare-new-technology-add-on-payment-302850312.html
- CMS, Fiscal Year 2027 Medicare Hospital Inpatient Prospective Payment System (IPPS) Final Rule, 91 FR 49570, published August 4, 2026. https://www.federalregister.gov/documents/2026/08/04/2026-15833/medicare-program-hospital-inpatient-prospective-payment-systems-for-acute-care-hospitals-ipps-and
- Radiology Business, "Medicare approves new technology add-on payment for inpatient radiology AI solution," August 14, 2026 (independent reporting on the final rule, citing the American College of Radiology's summary). https://radiologybusiness.com/topics/artificial-intelligence/medicare-approves-new-technology-add-payment-inpatient-radiology-ai-solution
This article summarizes a Medicare reimbursement decision and is not billing, financial, or legal advice. Hospitals should confirm case-specific eligibility and billing requirements with their own compliance and revenue cycle teams before relying on these figures.